GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » Total Liabilities

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Total Liabilities : $1.25 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Total Liabilities?

60 Degrees Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was $1.25 Mil.

60 Degrees Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2023 ($2.63 Mil) to Dec. 2023 ($2.99 Mil) but then declined from Dec. 2023 ($2.99 Mil) to Mar. 2024 ($1.25 Mil).

60 Degrees Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($19.55 Mil) to Dec. 2022 ($25.45 Mil) but then declined from Dec. 2022 ($25.45 Mil) to Dec. 2023 ($2.99 Mil).


60 Degrees Pharmaceuticals Total Liabilities Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Total Liabilities Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Liabilities
20.68 19.55 25.45 2.99

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.12 30.24 2.63 2.99 1.25

60 Degrees Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

60 Degrees Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.835+(0.15+0.0010000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.99

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=7.784-4.798
=2.99

60 Degrees Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.104+(0.149+0.00099999999999992
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.25

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=8.379-7.125
=1.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


60 Degrees Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Headlines